Andrew Latchford
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (30)
The St Mark’s Hospital Polyposis Registry was founded in 1924, the first such unit in the world. This paper documents the development of the unit over the subsequent 100 years, which was inextricably linked to scientific and clinical advance in the field of polyposis syndromes.
Year:
2025
APC c.3920T>A; p.Ile1307Lys (I1307K), prevalent in individuals of Ashkenazi Jewish (AJ) origin, has been associated with a modestly increased colorectal cancer (CRC) risk. Clinical recommendations for I1307K heterozygotes vary across countries and expert groups, reflecting differences in population frequencies, modest risk estimates, and limited data in non-AJ individuals. We analyzed UK Biobank data comprising 466,315 individuals (8,727 with CRC), using genomic analysis to classify AJ and non-AJ ancestries. I1307K was identified in 7.1% of AJ and 0.08% of non-AJ white participants. No significant association with CRC was observed in AJ (OR: 0.71; 95%CI: 0.17–2.95) or non-AJ white individuals (OR: 1.05; 95%CI: 0.50– 2.22). The previously established OR of 1.7–1.8 for AJ individuals lies within our 95% CI, indicating underpowered results due to limited CRC cases. No significant associations were detected for other cancers. Unbiased, adequately powered CRC case-control studies in non-AJ populations would require cohorts far larger than current resources for feasible analysis. Clinical actionability of I1307K should prioritize risk stratification based on overall CRC risk and ancestry-dependent variant detection rates. However, management strategies need not differ by ancestry once a carrier is identified, as the biological impact of I1307K should be consistent across populations.
Year:
2025
MUTYH ‐associated polyposis (MAP) is an autosomal recessive disorder where the inheritance of constitutional biallelic pathogenic MUTYH variants predisposes a person to the development of adenomas and colorectal cancer (CRC). It is also associated with extracolonic and extraintestinal manifestations that may overlap with the phenotype of familial adenomatous polyposis (FAP). Currently, there are discrepancies in the literature regarding whether certain phenotypes are truly associated with MAP. This narrative review is aimed at exploring the phenotypic spectrum of MAP to better characterize the MAP phenotype. Literature search was conducted to identify articles reporting on MAP‐specific phenotypes. Clinical data from 2109 MAP patients identified from the literature showed that 1123 patients (53.2%) had CRC. Some patients with CRC had no associated adenomas, suggesting that adenomas are not an obligatory component of MAP. Carriers of the two missense founder variants, and possibly truncating variants, had an increased cancer risk when compared to those who carry other pathogenic variants. It has been suggested that somatic G:C > T:A transversions are a mutational signature of MAP and could be used as a biomarker in screening and identifying patients with atypical MAP, or in associating certain phenotypes with MAP. The extracolonic and extraintestinal manifestations that have been associated with MAP include duodenal adenomas, duodenal cancer, fundic gland polyps, gastric cancer, ovarian cancer, bladder cancer, and skin cancer. The association of breast cancer and endometrial cancer with MAP remains disputed. Desmoid tumors and congenital hypertrophy of the retinal pigment epithelium (CHRPEs) are rarely reported in MAP but have long been seen in FAP patients and thus could act as a distinguishing feature between the two. This collection of MAP phenotypes will assist in the assessment of pathogenic MUTYH variants using the American College of Medical Genetics and the Association for Molecular Pathology (ACMG/AMP) Variant Interpretation Guidelines and ultimately improve patient care.
Year:
2024
Summary statistics for all FAP and MAP patient-derived intestinal samples analysed in this study. Data sets are from two centres, Cardiff University (CU) and MD Anderson Cancer Center (MDACC). Statistically significant P-values
Year:
2024
Overview of all intestinal samples used in this study. *Sequenced previously (Thomas et al, 2017) and reanalysed here. Somatic mutations in APC, KRAS and PIGA as identified by WES and WTS analysis of CU and MDACC duodenal adenomas. Samples where matched WTS data was available are indicated with * and those where the variant was present in both WES and WTS data are denoted with **. 1All protein changes refer to the respective canonical isoforms. 2CADD is a meta-estimator for the deleteriousness of SNVs and indels in the human genome. The score given here ranks a variant relative to all possible substitutions of the genome on a logarithmic scale, i.e. a variant with a score >10 is predicted to be amongst the 10% most deleterious mutations possible, a variant with a score >20 indicates the 1% most deleterious. The developers suggest a cut-off of 15 to identify potentially pathogenic variants (Kircher et al, 2014). C=Colectomy (exact surgical procedure unspecified); Can=Cancer; CRC=Colorectal cancer; DUO=Duodenum; H=Homozygous; IPAA=Ileoanal pouch anastomosis; IRA=Ileo-rectal anastomosis; IS=Ileostomy; PC=Proctocolectomy; NA=Not available, CADD=Combined Annotation Dependent Depletion; DEL=Deletion; FS=Frameshift, INS=Insertion; SNV=Single nucleotide variant; VAF=Variant allele frequency. WES. Whole exome sequencing only. WES/WTS. Whole exome and whole transcriptome sequencing. WTS. Whole transcriptome sequencing only
Year:
2024
Overview of all intestinal samples used in this study. *Sequenced previously (Thomas et al, 2017) and reanalysed here. Somatic mutations in APC, KRAS and PIGA as identified by WES and WTS analysis of CU and MDACC duodenal adenomas. Samples where matched WTS data was available are indicated with * and those where the variant was present in both WES and WTS data are denoted with **. 1All protein changes refer to the respective canonical isoforms. 2CADD is a meta-estimator for the deleteriousness of SNVs and indels in the human genome. The score given here ranks a variant relative to all possible substitutions of the genome on a logarithmic scale, i.e. a variant with a score >10 is predicted to be amongst the 10% most deleterious mutations possible, a variant with a score >20 indicates the 1% most deleterious. The developers suggest a cut-off of 15 to identify potentially pathogenic variants (Kircher et al, 2014). C=Colectomy (exact surgical procedure unspecified); Can=Cancer; CRC=Colorectal cancer; DUO=Duodenum; H=Homozygous; IPAA=Ileoanal pouch anastomosis; IRA=Ileo-rectal anastomosis; IS=Ileostomy; PC=Proctocolectomy; NA=Not available, CADD=Combined Annotation Dependent Depletion; DEL=Deletion; FS=Frameshift, INS=Insertion; SNV=Single nucleotide variant; VAF=Variant allele frequency. WES. Whole exome sequencing only. WES/WTS. Whole exome and whole transcriptome sequencing. WTS. Whole transcriptome sequencing only
Year:
2024
Somatic mutation rates in FAP and MAP-associated duodenal adenomas. A. Total, non-silent and silent mutation rate for all FAP and MAP adenomas. For FAP-associated duodenal adenomas, the average total mutation rate was 3.3 mutations per Mb (0.33-10.65 mutations/Mb), whilst for MAP adenomas, it was 4.9 mutations per Mb (0.94-15.1 mutations/Mb). The average non-silent mutational rate for FAP duodenal adenomas was 1.96 non-silent mutations/Mb (0.23-7.69 mutations/Mb), whilst for MAP adenomas it was 2.95 non-silent mutations/Mb (0.43-8.44 mutations/Mb). B. Differences in total, non-silent and silent mutational rates between the two diseases. There were no significant differences in total, non-silent and silent mutational rates between the two diseases. n.s. P>0.05; * P ≤0.05; ** P≤0.01; *** P ≤0.001.
Year:
2024
Flow cytometry analysis of FLAER positive cells in 11 FAP duodenal organoids with and without somatic PIGA variants. Fluorescence from FLAER is detected using the FITC-A channel (emission:475–650 nm). A, Abundance of FLAER positive cells detected in organoid lines with and without PIGA somatic mutations demonstrating lack of FLAER positive cells in PIGA mutant lines, indicating loss of GPI-anchors (Supplementary Table S2). B, Representative histogram of FITC-A/FLAER (selecting for FLAER positive cells), light grey = wild-type adenoma, dark grey = PIGA mutant adenoma. Repeats are denoted with a black triangle, circle, and square.
Year:
2024
A, PIGA mutations identified in 19 duodenal adenomas and two duodenal adenoma patient-derived organoid lines. Relative location in comparison with known protein domains is shown. B, The VAF of four types of somatic mutation (exonic − synonymous/missense + indels/nonsense; all other mutations) for all adenomas analyzed from FAP and MAP patients. For each duodenal adenoma sample, all somatic mutations are shown as circles indicating the allelic frequency of the respective mutant alleles. The median VAF per sample is represented with a red bar. The APC VAFs are indicated in blue and PIGA in purple. The total number of somatic mutations in each adenoma sample is displayed in the lower graph.
Year:
2024
RNASeq WTS pipeline validation by quantitative RT-PCR (qRT-PCR) and IHC A. Comparison of normalised RNA-Seq read counts (orange) to relative qRT-PCR expression levels (purple) for four top DEGs. Δ CT values are shown, with low values indicative of low mRNA abundances. High concordance between the two methods can be observed. qRT-PCR confirms increased levels of S100P and KRT7 and decreased levels of FCER2 and CA4 mRNA in duodenal adenomas in comparison to normal duodenal mucosa samples (purple bars). B. IHC results for S100 and CK7 expression in duodenal normal mucosa or duodenal adenoma tissue sections. Moderate and relatively strong positive staining for CK7 and S100, respectively, was also confirmed in duodenal adenomas compared to corresponding normal duodenal mucosa samples. Representative samples that had undergone RNA-Seq are shown. Scale bar: 50μm. COL=Colorectal samples; DUO=Duodenal samples
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (12)
Emma Short
-
Melissa Taggart
Associate professor
The University of Texas MD Anderson Cancer Center
gareth jenkins
Professor
Swansea University
Matthew Mort
Cardiff University
Laura Valle
Institut d'Investigacions Biomèdiques de Barcelona
Clare Turnbull
Professor in Translational Cancer Genetics
Institute of Cancer Research
Eduardo Vilar
Assistant Professor
The University of Texas MD Anderson Cancer Center
Patrick Lynch
Professor
The University of Texas MD Anderson Cancer Center
Maartje Nielsen
Clinical geneticist
Leiden University Medical Center
Nicholas Jones
Swansea University
Hannah Deborah West
Senior Lecturer
Cardiff University
Laura Thomas
Senior Lecturer
Swansea University
Make your next move.
Prepare your application
Review drafts before you send them.